Pulmonary Drug Delivery Systems 2016-2022: Technologies and Global Markets Report 2018

DUBLIN, May 1, 2018 /PRNewswire/ --

The "Pulmonary Drug Delivery Systems: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The market for pulmonary drug delivery systems is witnessing growth due to the rising prevalence of respiratory disorders such as asthma, COPD and other chronic illnesses. Other factors that are driving the growth of the market are the emergence of novel inhaler designs and increased use of non-invasive drug delivery methods.

Pulmonary drug delivery is an alternative to oral drug delivery. Pulmonary drug delivery is primarily advantageous for the treatment of respiratory diseases due to systemic administration via fast absorption by the alveolar region. The pulmonary drug delivery method depends on the development of simple, cost effective and easy to use devices.

These devices are designed to facilitate consistent drug delivery with increased lung penetration and multi-dosage facilities. Currently, manufacturers are concentrating on the development of small, portable devices that encourage higher patient compliance. The World Health Organization (WHO) estimates that there were approximately 251 million people suffering from COPD globally in 2016.

It is estimated by the WHO that nearly 3.17 million deaths occurred in 2015 due to the disease itself. The primary cause of the disease is smoking tobacco. The growing number of smokers in developing economies is increasing the incidence of the disease.

Report Includes:

• A detailed overview and analysis of the global markets for pulmonary drug delivery systems
• Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
• Assessments of pulmonary drug delivery systems by regions, delivery systems/types, and disease areas
• A look at the regulatory environment, which has been a driving force in the healthcare industry
• Reviews of key developments, novel product innovations, and recent strategic industry activities of major players across various product categories
• Detailed profiles of major vendors in the market, including 3M Pharmaceuticals Inc., AstraZeneca plc, Cipla Inc., GlaxoSmithKline plc and Lupin Ltd

Market Dynamics

Limitations/Challenges

• Pulmonary Conditions and Therapies
• Introduction to the Respiratory System

Market Driving Factors and Trends

• Improved Patient Compliance and Ease of Use Leading to Adoption of Inhalation Products
• Cost Pressure on Countries Imposing Adoption of Cost-Effective Devices
• Rising Incidence of Asthma and COPD in Developing and Developed Regions

Market Restraints

• Competition from Generics on the Rise Due to Patent Expiry of Blockbuster Products

Market Opportunities

• Introduction of Smart Nebulizers
• Regulation and Legislation

Key Topics Covered:

1 Introduction

2 Summary and Highlights

3 Market Dynamics and Technology Background

4 Market Breakdown by Pulmonary Drug Delivery Systems

5 Pulmonary Drug Delivery Drugs in Use

6 Market Breakdown by Disease Area

7 Market Breakdown by Region

8 Competitive Landscape and Key Developments

9 Company Profiles

• 3M Pharmaceuticals, Inc.
• Astrazeneca Plc
• Boehringer Ingelheim Gmbh
• Cipla, Inc.
• Dr. Reddy's Laboratories Ltd.
• Glaxosmithkline Plc
• Koninklijke Philips N.V. (Respironics, Inc.)
• Lupin, Limited
• Mylan N.V.
• Novartis Ag
• Omron Corporation
• Pfizer, Inc.
• Pulmatrix, Inc.
• Teva Pharmaceutical Industries, Ltd.
• Vectura Group Plc
  

For more information about this report visit https://www.researchandmarkets.com/research/m2fl8r/pulmonary_drug?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com